Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis
生物材料介导的 R-spondin 2 持续抑制对创伤后骨关节炎中病理性 Wnt 信号传导的影响
基本信息
- 批准号:10704167
- 负责人:
- 金额:$ 52.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAdvanced DevelopmentAgonistAntidepressive AgentsArthralgiaAttenuatedBenchmarkingBindingBiocompatible MaterialsBiologicalBiomedical EngineeringBone SpurCartilageCellsChondrocytesClinical TrialsConditioned Culture MediaDataDevelopmentDiseaseDisease ProgressionDoctor of PhilosophyDoseDrug ScreeningEngineeringFibroblastsFibrosisFormulationG-Protein-Coupled ReceptorsGene ExpressionGenetic TranscriptionGlycolatesHistologyHumanHypertrophyIL6 geneIn VitroInflammatoryInjectionsInjuryIntra-Articular InjectionsJointsKneeKnockout MiceLGR5 geneLeucine-Rich RepeatLigandsLiteratureLocal TherapyMacrophageMatrix MetalloproteinasesMediatingMetabolic Clearance RateMicrospheresMolecularMusOperative Surgical ProceduresOsteoblastsOsteogenesisPathogenesisPathogenicityPathologicPathway interactionsPatientsPeptide HydrolasesPharmaceutical PreparationsPhenotypeProcessRattusReporterResearchResearch PersonnelRoleSafetySclerosisSeveritiesSignal PathwaySignal TransductionSynovial FluidSynovial MembraneSynovitisTNF geneTestingTherapeuticTimeTissuesTraumatic ArthropathyWNT Signaling Pathwayarthropathiesbeta cateninbiomaterial compatibilitybonebone cellcartilage degradationcell typeconditional knockoutdelivery vehicleeffective therapyefficacy testingin vivoinhibitorinhibitor therapyjoint destructionjoint injuryknee painknee replacement arthroplastynovelosteoblast differentiationosteoprogenitor celloverexpressionpharmacokinetics and pharmacodynamicsreceptorresponsesafety assessmentsingle-cell RNA sequencingsmall moleculesolutesubchondral bonetherapy developmenttissue regeneration
项目摘要
ABSTRACT
INVESTIGATORS: Tristan Maerz, PhD (PI) is an ESI biomedical engineer focused on developing new treat-
ments for post-traumatic osteoarthritis (PTOA). The Co-Investigators Kurt Hankenson, DVM PhD and Craig
Duvall, PhD have expertise in Wnt signaling and biomaterial-mediated tissue regeneration, respectively.
RESEARCH CONTEXT: Overactivation of canonical Wnt/β-Catenin (cWnt) signaling is increasingly recognized
as a driver of joint degeneration in PTOA. A novel cWnt agonist in the context of PTOA is R-spondin 2
(Rspo2), which some literature and our data support as a disease-promoting ligand via cWnt-mediated induc-
tion of synovial fibrosis, protease overexpression, chondrocyte hypertrophy, and aberrant bone sclerosis. A
recent drug screen identified that the drug Mianserin inhibits Rspo2 signaling by blocking Lgr5 binding. Given
high solute clearance rates in the joint, we must engineer new depot-type formulations using biomaterials to
deliver small molecules such as Mianserin. Poly(lactic-co-glycolic acid) (PLGA) microspheres are a versatile
and biocompatible delivery vehicle well-suited to deliver molecules to the joint, and they can be engineered to
deliver Mianserin for sustained intra-articular cWnt pathway inhibition by targeting Rspo2 signaling.
OBJECTIVE: To validate the role of Rspo2 in PTOA pathogenesis and test efficacy of sustained intra-articular
Rspo2 inhibition using Mianserin-loaded PLGA microspheres.
SPECIFIC AIMS: 1). Elucidate the impact of Rspo2 on PTOA progression; 2). Advance the development of
PLGA microspheres to achieve sustained in vivo delivery of a small-molecule Rspo2 inhibitor; 3). Test the effi-
cacy of sustained intra-articular Rspo2 inhibitor therapy as a novel PTOA treatment.
RESEARCH PLAN: Aim 1). We will delineate Rspo2-responsive cell types and characterize the disease-pro-
moting effect of Rspo2 in healthy and injured joints of TCF/LEF Wnt reporter mice. Single-cell RNAseq will elu-
cidate Rspo2-Lgr signaling cells while unbiasedly assessing transcriptional responses to Rspo2. Rspo2 will
then be ablated globally at the time of joint injury using Rosa26-CreERT2; Rspo2f/f mice and PTOA severity will
be assessed. Aim 2). We will formulate Mianserin-loaded PLGA microspheres, aiming to achieve >4 weeks of
in vitro release with negligible burst. We will confirm 4 weeks of in vivo cWnt signaling suppression and assess
safety. Using primary cells, we will examine the effect of sustained Mianserin delivery on cWnt signaling in
chondrocytes, synovial fibroblasts, and osteoprogenitor cells. We will further test PLGA-based Mianserin deliv-
ery on Rspo2-treated human cartilage explants obtained during total knee arthroplasty. Aim 3). We will admin-
ister Mianserin-loaded PLGA microspheres to the joint following injury and comprehensively phenotype PTOA,
benchmarking efficacy against repeated Mianserin and repeated β-Catenin inhibitor injections. We will verify
that the in vivo effect of Mianserin is mediated through Rspo2 inhibition by performing these studies in WT and
Rspo2 conditional knockout mice, and we will confirm suppression of cWnt signaling using IHC.
抽象的
调查员:Tristan Maerz 博士(PI)是一名 ESI 生物医学工程师,专注于开发新的治疗方法
共同研究者 Kurt Hankenson(DVM 博士)和 Craig 共同研究了创伤后骨关节炎 (PTOA)。
Duvall 博士分别在 Wnt 信号传导和生物材料介导的组织再生方面拥有专业知识。
研究背景:人们越来越认识到经典 Wnt/β-Catenin (cWnt) 信号传导的过度激活
R-spondin 2 是 PTOA 中关节退化的驱动因素。
(Rspo2),一些文献和我们的数据支持其通过 cWnt 介导的诱导作用作为促进疾病的配体
滑膜纤维化、蛋白酶过度表达、软骨细胞肥大和异常骨硬化。
最近的药物筛选发现,药物 Mianserin 通过阻断 Lgr5 结合来抑制 Rspo2 信号传导。
由于关节中的溶质清除率较高,我们必须使用生物材料设计新的储库型配方,以
提供小分子,如米安舍林 (PLGA) 微球是一种多功能的药物。
和生物相容性输送载体非常适合将分子输送到关节,并且它们可以被设计为
通过靶向 Rspo2 信号传导,递送米安色林以持续抑制关节内 cWnt 通路。
目的:验证Rspo2在PTOA发病机制中的作用并测试持续关节内注射的疗效。
使用负载 Mianserin 的 PLGA 微球抑制 Rspo2。
具体目标: 1) 阐明 Rspo2 对 PTOA 进展的影响;
PLGA微球实现小分子Rspo2抑制剂的持续体内递送3)。
持续关节内 Rspo2 抑制剂治疗作为新型 PTOA 治疗的有效性。
研究计划:目标 1) 我们将描述 Rspo2 反应细胞类型并表征疾病相关细胞。
Rspo2 在 TCF/LEF Wnt 报告小鼠的健康和受伤关节中的运动效应将被洗脱。
cidate Rspo2-Lgr 信号细胞,同时公正地评估 Rspo2 的转录反应。
然后使用 Rosa26-CreERT2 小鼠在关节损伤时进行全局消融,PTOA 严重程度将降低;
目标 2) 我们将配制负载 Mianserin 的 PLGA 微球,旨在实现 > 4 周的效果。
我们将确认 4 周的体内 cWnt 信号传导抑制并评估。
使用原代细胞,我们将检查持续递送米安色林对 cWnt 信号传导的影响。
我们将进一步测试基于 PLGA 的 Mianserin deliv-。
我们将在全膝关节置换术中获得 Rspo2 处理的人类软骨外植体。
将负载 Mianserin 的 PLGA 微球注射到损伤后的关节并进行综合表型 PTOA,
我们将验证重复注射米安舍林和重复 β-连环蛋白抑制剂的基准疗效。
通过在 WT 和
Rspo2 条件敲除小鼠,我们将使用 IHC 确认 cWnt 信号传导的抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tristan Maerz其他文献
Tristan Maerz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tristan Maerz', 18)}}的其他基金
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis
生物材料介导的 R-spondin 2 持续抑制对创伤后骨关节炎中病理性 Wnt 信号传导的影响
- 批准号:
10518062 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
相似国自然基金
减少编程错误:基于认证内核的全新的快捷依赖类型PiSigma高级编程语言开发
- 批准号:61070023
- 批准年份:2010
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis
生物材料介导的 R-spondin 2 持续抑制对创伤后骨关节炎中病理性 Wnt 信号传导的影响
- 批准号:
10518062 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
Ceramide NanoLiposomes as a novel therapeutic for prostate cancer
神经酰胺纳米脂质体作为前列腺癌的新型治疗方法
- 批准号:
10640860 - 财政年份:2021
- 资助金额:
$ 52.07万 - 项目类别:
Chemical Epigenomic Strategies to Overcome Metastatic Castration Resistant Prostate Cancer
克服转移性去势抵抗性前列腺癌的化学表观基因组策略
- 批准号:
10611442 - 财政年份:2021
- 资助金额:
$ 52.07万 - 项目类别:
Ceramide NanoLiposomes as a novel therapeutic for prostate cancer
神经酰胺纳米脂质体作为前列腺癌的新型治疗方法
- 批准号:
10393834 - 财政年份:2021
- 资助金额:
$ 52.07万 - 项目类别:
Ceramide NanoLiposomes as a novel therapeutic for prostate cancer
神经酰胺纳米脂质体作为前列腺癌的新型治疗方法
- 批准号:
10413258 - 财政年份:2021
- 资助金额:
$ 52.07万 - 项目类别: